COLLPLANT BIOTECH. IS-01 (CPT) - Total Liabilities
Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has total liabilities worth €4.70 Million EUR (≈ $5.50 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are COLLPLANT BIOTECH. IS-01's assets to evaluate the company's liquid asset resilience ratio.
COLLPLANT BIOTECH. IS-01 - Total Liabilities Trend (2021–2025)
This chart illustrates how COLLPLANT BIOTECH. IS-01's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of COLLPLANT BIOTECH. IS-01.
COLLPLANT BIOTECH. IS-01 Competitors by Total Liabilities
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gratomic Inc
V:GRAT
|
Canada | CA$7.10 Million |
|
BIRKS GROUP INC. A
F:2BG
|
Germany | €235.71 Million |
|
Cascadero Copper Corp
V:CCD
|
Canada | CA$863.86K |
|
Tsodilo Resources Limited
V:TSD
|
Canada | CA$4.77 Million |
|
SaverOne 2014 Ltd. American Depositary Shares
NASDAQ:SVRE
|
USA | $8.68 Million |
|
Binani Industries Limited
NSE:BINANIIND
|
India | Rs2.02 Billion |
|
Kedaung Indah Can Tbk
JK:KICI
|
Indonesia | Rp100.38 Billion |
|
K9 Gold Corp
V:KNC
|
Canada | CA$110.11K |
Liability Composition Analysis (2021–2025)
This chart breaks down COLLPLANT BIOTECH. IS-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of COLLPLANT BIOTECH. IS-01 to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COLLPLANT BIOTECH. IS-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual total liabilities of COLLPLANT BIOTECH. IS-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.70 Million ≈ $5.50 Million |
-10.31% |
| 2024-12-31 | €5.25 Million ≈ $6.13 Million |
-9.35% |
| 2023-12-31 | €5.79 Million ≈ $6.76 Million |
+5.45% |
| 2022-12-31 | €5.49 Million ≈ $6.41 Million |
-10.09% |
| 2021-12-31 | €6.10 Million ≈ $7.14 Million |
-- |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more